EUGENE2 is a well focused, cohesive and multidimensional effort whereby top European laboratories, together with the biotechnology industry, are united in a collaborative scheme to achieve a critical mass and to consolidate Europe's position as an international leader in the field of Type 2 diabetes and its pathogenesis. With this aim in view, EUGENE2 will group and network experts in functional genomics, genomics, proteomics and bioinformatics to achieve a critical mass to unravel the complex pathogenesis of Type 2 diabetes and the specific role of the skeletal muscle, fat and the liver. In practice, this will involve the dedication and the development of common research infrastructures in human and rodent genomics and bioinformatics combined with cohesive research efforts in proteomics, transcriptional regulation, insulin signaling and action in the target-tissues. A concerted effort in applying functional genomic approaches in humans, rodents and target cells will generate information necessary to make advances in health care, pharmaceutical development and public health policies.'
|
